Article in Lab animal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Joel JovanovicVanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, TN, USA. joel.jovanovic@vumc.org.ORCID 0000-0002-9195-2239
Megan L StoneDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA.
Samantha R DooyemaVanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, TN, USA.
Yuankai K TaoVanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, TN, USA.
Sabine FuhrmannVanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-2456-5490
Edward M LevineVanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, TN, USA. ed.levine@vanderbilt.edu.ORCID 0000-0003-1725-2805
Funding
Shop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI David J. Calkins · 1989 to 2026
$19.6M
Vsx2 Dependent Regulation of Retinal Progenitor Cell PropertiesR01EY013760 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LEVINE, EDWARD M · 2003 to 2024
$6.9M
Regulation of Eye MorphogenesisR01EY024373 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SABINE FUHRMANN · 2015 to 2026
$3.4M
Point-of-care ophthalmic diagnostic imaging of retinopathy of prematurityR01EY033969 · NEI · VANDERBILT UNIVERSITY · PI Ipek Oguz, Yuankai Kenny Tao · 2023 to 2026
$2.3M
Intraoperative Optical Coherence Tomography for Ophthalmic Surgical GuidanceR01EY030490 · NEI · VANDERBILT UNIVERSITY · PI TAO, YUANKAI KENNY · 2019 to 2023
$1.8M
Intraoperative imaging of macular hole repair to predict visual function outcomesR01EY031769 · NEI · VANDERBILT UNIVERSITY · PI TAO, YUANKAI KENNY · 2020 to 2023
$1.4M
Neurogenic potential of murine Müller glia following retinal injury and conditional inactivation of p27Kip1R21EY033473 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LEVINE, EDWARD M · 2022 to 2023
$476k
International Retinal Research Foundation (International Retinal Research Foundation, Inc.) 2023 Loris and David Rich Postdoctoral Scholar AwardNEI NIH HHS P30 EY008126NEI NIH HHS R01 EY013760NEI NIH HHS R01 EY024373NEI NIH HHS R01 EY030490NEI NIH HHS R01 EY031769NEI NIH HHS R01 EY033969NEI NIH HHS R21 EY033473U.S. Department of Health & Human Services | NIH | National Eye Institute (NEI) R01-EY013760-S1U.S. Department of Health & Human Services | NIH | National Eye Institute (NEI) R01EY024373U.S. Department of Health & Human Services | NIH | National Eye Institute (NEI) R01EY030490U.S. Department of Health & Human Services | NIH | National Eye Institute (NEI) R01EY031769U.S. Department of Health & Human Services | NIH | National Eye Institute (NEI) R01EY033969U.S. Department of Health & Human Services | NIH | National Eye Institute (NEI) R21-EY033473
6 · The paper itself
Abstract
Small molecules such as PLX5622 for microglia depletion and tamoxifen for inducible Cre recombination are commonly used in mouse research. Traditional application methods such as drug-infused chow, oral gavage or injections have limitations, including uncontrolled dosing (chow) or risk of injury and/or stress (gavage or injections). Here, to address these issues, we have developed an alternative oral drug delivery system using a gel-based rodent maintenance diet that allows for controlled consumption and adjustment of dosage and is suitable for water-insoluble small molecules. We tested DietGel 93M (93M) infused with PLX5622 (0.8 mg/g and 2.0 mg/g) in the Cx3cr1
Indexed as
Drug Delivery SystemsIntegrasesMicrogliaRecombination, GeneticTamoxifenAdministration, OralAnimalsDietFemaleGelsMaleMiceMice, Inbred C57BLMice, TransgenicafimoxifeneCre recombinaseGelsIntegrasesTamoxifen
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Diet gel-based oral drug delivery system for controlled dosing of small molecules for microglia depletion and inducible Cre recombination in mice. · full record | OpenQuestion